Comparative study of the effect of tranexamic acid and exogenous fibrin monomer on fibrin formation in the injury area during stimulation of fibrinolysis by streptokinase

Introduction. Earlier studies of low-dose fibrin monomer (FM) demonstrated that low-dose FM has unique hemostatic properties in vivo.

Aim — to compare the morphological consequences of intravenous administration of tranexamic acid (TXA) and FM with the hemostatic and hemostasiological effects in hypofibrinogenemia caused by the use of streptokinase after controlled liver injury.

Materials and methods. The morphological pattern of fibrin formation in the liver injury area after spontaneous arrest of bleeding in the animals treated with streptokinase or placebo was studied in 73 male rabbits of the Chinchilla breed, split into four groups. In three groups, the study was performed under the conditions of intravenous administration of placebo, TXA, or FM against the background of fibrinolysis activation by streptokinase. Platelet count in the blood, the concentration of fibrinogen, as well as the results of calibrated thrombography, were taken into account.

Results. Sequential administration of streptokinase and TXA was accompanied by decreased fibrinogen concentration (by 29.6 %) and, at the same time, a reduction in blood loss (by 15.4 times) in comparison with animals where placebo was used instead of TXA. A decrease in blood loss was associated with increased thickness of thrombotic deposits at the edge of the wound, mainly consisting of red blood cells. These observations were combined with data on the acceleration of thrombin formation in venous blood plasma in a calibrated thrombography test (Peak thrombin 65.4 nmol/L to 109.6 nmol/L in the placebo group). Compared to the observations where placebo was administered instead of FM, however, the sequential use of streptokinase and FM also led to a decrease in blood loss (by 11.0 times) despite decreased fibrinogen concentration (by 23.3 %). A decrease in blood loss was also associated with platelet consumption in venous blood and with increased thickness of thrombotic deposits on the injury surface, where, in addition to red blood cells, the accumulation of fibrin masses was determined by the morphological pattern.

Conclusion. The mechanisms of the systemic hemostatic effect of TXA and FM are different, despite the similarity of the achieved hemostatic effects in the conditions of stimulation of blood fibrinolytic activity. These findings expand the understanding of new therapeutic possibilities for reducing post-traumatic blood loss.

1. Hoffman M., Monroe D.M. A cell-based model of hemostasis. Thromb Haemost. 2001; 85: 958–65. DOI: 10.1055/s-0037-1615947.

2. Butylin A.A., Panteleev M.A., Ataullakhanov F.I. Spatial dynamics of blood clotting. Rossijskij himicheskij zhurnal. 2007; LI(1): 45–50. (In Russian).

3. Momot A.P., Vdovin V.M., Momot D.A., et al. New opportunities to reduce blood loss with systemic administration of low-dose fibrin monomer. Klinicheskaya fiziologiya krovoobrashheniya. 2019; 16(4): 267–73. DOI: 10.24022/1814-6910-2019-16-4-267-273. (In Russian).

4. Vdovin V.M., Momot A.P., Orekhov D.A., et al. Posttraumatic bleeding reduction by systemic administration of fibrin monomer in thrombolytic therapy in the experiment. Patologiya krovoobrashheniya i kardiohirurgiya. 2020; 24(1): 78–86. DOI: 10.21688/1681-3472-2020-1-78-86. (In Russian).

5. Kyoung-Jin P., Eui-Hoon K., Hee-Jin K., Sun-Hee K. Evaluation of the diagnostic performance of fibrin monomer in disseminated intravascular coagulation. Korean J Lab Med. 2011; 31(3): 143–7. DOI: 10.3343/kjlm.2011.31.3.143.

6. Vdovin V.M., Momot A.P., Orehov D.A., et al. Effect of exogenous fibrin monomer on hemostatic potential and fibrin formation in the area of controlled liver injury in the experiment. Rossijskij fiziologicheskij zhurnal. 2020; 106(9): 1132–43. DOI: 10.31857/S0869813920070092. (In Russian).

7. Hunt B.J. The current place of tranexamic acid in the management of bleeding. Anaesthesia. 2015; 70(Suppl. 1): 50–3. DOI: 10.1111/anae.12910.

8. Ramirez R.J., Spinella P.C., Bochicchio G.V. Tranexamic acid update in trauma. Crit Care Clin. 2017; 33(1): 85–99. DOI: 10.1016/j.ccc.2016.08.004.

9. Mironov A.N. Guidelines for conducting preclinical studies of drugs. Part 1. Moscow: Grif and K; 2012: 944 р. (In Russian).

10. Momot A.P., Shakhmatov I.I., Lomaev I.S., Terekhov S.S. A method for the industrial production of fibrin monomer from blood plasma Patent of the Russian Federation № 2522237. 2014; Bul. No. 19. (In Russian).

11. Khabriev R.U. Guidelines for experimental (preclinical) study of new pharmacological substances. 2nd ed. Moscow: Meditsina; 2005: 828 p. (In Russian).

12. Kopaladze R.A. Methods of euthanasia of experimental animals. Ethics, esthetics and personnel safety. Uspehi fiziologicheskih nauk. 2000; 31(3): 79–90. (In Russian).

13. Zerbino D.D., Lukasevich L.L. Disseminated intravascular coagulation: Facts and concepts. Moscow: Meditsina; 1989: 256 р. (In Russian).

14. Kuznik B.I. Cellular and molecular regulation mechanisms of hemostasis system in health and disease. Chita: Ehkspress-izdatel’stvo; 2010: 832 р. (In Russian).

15. Kuznik B.I., Sturov V.G. Levshin N.Ju., et al. Hemorrhagic and thrombotic diseases in childhood and adolescence. Novosibirsk: Nauka; 2018: 524 р. (In Russian).

16. Collet J.P., Park D., Lesty C., et al. Infl uence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol. 2000; 20 (5): 1354–61. DOI: 10.1161/01.ATV.20.5.1354.

17. Wolberg A.S. Thrombin generation and fibrin clot structure. Blood Rev.2007; 21(3): 131–42. DOI: 10.1016/j.blre.2006.11.001.